GoodRx (NASDAQ:GDRX) Shares Gap Down – Here’s Why

GoodRx Holdings, Inc. (NASDAQ:GDRX)’s share price gapped down prior to trading on Thursday . The stock had previously closed at $2.58, but opened at $2.50. GoodRx shares last traded at $2.5750, with a volume of 965,560 shares traded.

Analyst Upgrades and Downgrades

GDRX has been the topic of a number of recent analyst reports. Barclays initiated coverage on shares of GoodRx in a report on Monday, December 8th. They set an “underweight” rating and a $3.00 price target on the stock. Mizuho lowered their price target on GoodRx from $5.00 to $4.00 and set a “neutral” rating on the stock in a report on Thursday, November 6th. UBS Group reaffirmed a “reduce” rating on shares of GoodRx in a report on Monday, January 5th. TD Cowen reduced their price objective on GoodRx from $7.00 to $6.00 and set a “buy” rating for the company in a research report on Monday, November 10th. Finally, Morgan Stanley cut their price target on GoodRx from $5.00 to $4.00 and set an “equal weight” rating for the company in a research note on Thursday, December 18th. Five investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $4.73.

GoodRx Stock Performance

The company has a market cap of $877.43 million, a PE ratio of 28.72, a PEG ratio of 0.99 and a beta of 1.45. The company has a current ratio of 3.11, a quick ratio of 3.11 and a debt-to-equity ratio of 0.81. The business’s 50 day moving average is $2.76 and its two-hundred day moving average is $3.69.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The business had revenue of $196.03 million for the quarter, compared to the consensus estimate of $195.17 million. GoodRx had a net margin of 3.97% and a return on equity of 9.73%. GoodRx’s revenue was up .4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.08 earnings per share. On average, equities research analysts anticipate that GoodRx Holdings, Inc. will post 0.13 EPS for the current year.

Institutional Investors Weigh In On GoodRx

Several institutional investors and hedge funds have recently modified their holdings of the stock. Quarry LP bought a new position in shares of GoodRx during the 3rd quarter valued at about $33,000. Boothbay Fund Management LLC purchased a new position in GoodRx during the 3rd quarter valued at approximately $43,000. Shay Capital LLC bought a new stake in GoodRx in the 3rd quarter worth approximately $47,000. Cetera Investment Advisers purchased a new stake in shares of GoodRx during the 2nd quarter worth approximately $50,000. Finally, Walled Lake Planning & Wealth Management LLC bought a new position in shares of GoodRx during the 2nd quarter valued at approximately $55,000. Institutional investors own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.